Journal article

Antidepressant pharmacogenetics

Ajeet B Singh, Chad A Bousman, Chee Ng, Michael Berk

CURRENT OPINION IN PSYCHIATRY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014

Abstract

PURPOSE OF REVIEW: This article reviews recent literature published over the period March 2012-August 2013 on antidepressant pharmacogenetics, with a focus on clinical translation and methodological challenges. RECENT FINDINGS: Recently, various polymorphisms associated with differential antidepressant efficacy, tolerability, and safety have emerged in association studies, but mixed findings, limited effect sizes, and poor control of confounders have prevented findings translating to practice. Although promising steps have been made, empirically robust clinically translatable pharmacogenetic tests are not yet established. The complex neurobiology of major depressive disorder (MDD) together w..

View full abstract

Grants

Funding Acknowledgements

C. N. served the Wyeth and Eli Lilly Advisory Boards, received research grant support from Wyeth and Lundbeck and speaker honoraria from Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Astra-Zenaca, Wyeth and Pfizer.r M. B. is Alfred Deakin Professor of Psychiatry, Deakin University, Professorial Research Fellow, Mental Health Research Institute, Orygen Research Centre and the University of Melbourne. He is consultant to Astra Zeneca, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck and Servier; and is on the speaker's bureau of AstraZeneca, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Pfizer, Sanofi, Synthlabo, Servier, Solvay and Wyeth; he has received grant/research support from Astra Zeneca, Beyond Blue, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Mayne Pharma, MBF Bioscience, National Health and Medical Research Council, Novartis, Organon, Servier and Stanley Medical Research Foundation; and has received honoraria from AstraZeneca, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Pfizer, Sanofi, Synthlabo, Servier, Solvay, and Wyeth.